These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 31435176)

  • 1. Natural history of children with mild Crohn's disease.
    Sharma Y; Bousvaros A; Liu E; Bender Stern J
    World J Gastroenterol; 2019 Aug; 25(30):4235-4245. PubMed ID: 31435176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current therapy of inflammatory bowel disease in children.
    Rufo PA; Bousvaros A
    Paediatr Drugs; 2006; 8(5):279-302. PubMed ID: 17037946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review and update on Crohn's disease.
    Gajendran M; Loganathan P; Catinella AP; Hashash JG
    Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
    Rivière P; D'Haens G; Peyrin-Biroulet L; Baert F; Lambrecht G; Pariente B; Bossuyt P; Buisson A; Oldenburg B; Vermeire S; Laharie D
    Am J Gastroenterol; 2021 Jan; 116(1):134-141. PubMed ID: 33177349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation does not alter histology in resected Crohn's disease.
    Frizelle FA; Ing A; Gearry RB; Whitehead M; Faragher IG; Dobbs B
    Tech Coloproctol; 2009 Dec; 13(4):295-300. PubMed ID: 19774438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Mucosal Healing with Exclusive Enteral Nutrition is Associated with Improved Outcomes in Newly Diagnosed Children with Luminal Crohn's disease.
    Grover Z; Burgess C; Muir R; Reilly C; Lewindon PJ
    J Crohns Colitis; 2016 Oct; 10(10):1159-64. PubMed ID: 26980840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of pathologic features associated with "ulcerative colitis-like" Crohn's disease.
    James SD; Wise PE; Zuluaga-Toro T; Schwartz DA; Washington MK; Shi C
    World J Gastroenterol; 2014 Sep; 20(36):13139-45. PubMed ID: 25278708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
    Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J
    Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients.
    Aguas M; Bastida G; Cerrillo E; Beltrán B; Iborra M; Sánchez-Montes C; Muñoz F; Barrio J; Riestra S; Nos P
    World J Gastroenterol; 2012 Aug; 18(32):4391-8. PubMed ID: 22969204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailoring Crohn's disease treatment: the impact of small bowel capsule endoscopy.
    Cotter J; Dias de Castro F; Moreira MJ; Rosa B
    J Crohns Colitis; 2014 Dec; 8(12):1610-5. PubMed ID: 24631311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.
    Zittan E; Kabakchiev B; Milgrom R; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    J Crohns Colitis; 2016 May; 10(5):510-5. PubMed ID: 26783345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease.
    Saad AM; Czul F; Sakuraba A; Rubin DT; Cohen RD
    Inflamm Bowel Dis; 2016 May; 22(5):1027-31. PubMed ID: 26919459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.
    Harris RE; Aloi M; de Ridder L; Croft NM; Koletzko S; Levine A; Turner D; Veereman G; Neyt M; Bigot L; Ruemmele FM; Russell RK;
    BMJ Open; 2020 Jul; 10(7):e034892. PubMed ID: 32611737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
    Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
    World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.